Measurement of Kidney Blood Flow and Oxygen Levels by MRI

Chronic Kidney Disease Clinical Trial

Official title:

MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01318967
• Other study ID #: IRB00010832
• Status: Completed
• Phase: N/A
• Start date: October 2010
• Est. completion date: June 2013

Study information

• Verified date: August 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparison of renal blood flow measurements by PAH clearance and MRI

Description:

The traditional measurement of renal blood flow in ml/min involves the collection of multiple blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is given. In this study, the investigators determine the ability of MRI to estimate renal blood flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both performed on the same day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2013
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

In this study, the investigators will enroll 16 men and women aged = 18 years with Stage II

• V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any evidence of CKD.

Exclusion Criteria:

This study excludes those not suitable for MRI or for the interventional pharmacologic procedures.

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Furosemide
Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.

Other:
• Placebo

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of Renal Blood Flow of the Kidney by the PAH Method	Renal blood flow is estimated by the PAH method.	Renal blood flow is estimated over 1 hour by PAH
Secondary	Measurement of Regional Blood Oxygenation by MRI	Estimate of renal blood flow by using MRI scans before and after the administration of furosemide	One measure after furosemide (day 1)